CorMedix (CRMD) said Monday that its large dialysis organization customer has begun ordering and will start implementing DefenCath in H2 2025, targeting at least 50% more patients than previously planned.
The company said it had amended its agreement with the organization to reflect this broader rollout, which is expected to contribute modestly to June revenue and drive stronger growth in the second half of the year.
Due to the expanded implementation, CorMedix has raised its Q2 net sales guidance to a range of $35 million to $40 million from $31 million.
Shares of the company were up 15.5% in Monday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.